http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
ARIAD’s Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival in ALTA Study
-
ARIAD Announces Data Presentations at American Society of Hematology Meeting
-
ARIAD Pharma (ARIA) Announces Presentation of Brigatinib Phase 1/2, ALTA Trial Data; ORRs of 53% and 67% Noted
-
ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer
-
ARIAD to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer
-
ARIAD Pharma's (ARIA) Iclusig Granted Full FDA Approval
-
ARIAD Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial
-
ARIAD Announces Data Presentations at the World Conference on Lung Cancer
-
ARIAD Announces Launch of Inaugural ALK+ Day During Lung Cancer Awareness Month
-
ARIAD Pharma (ARIA) Announces Publication of Brigatinib Phase 1/2 Data; Median PFS Observed at 1+ Year
-
ARIAD Announces Phase 1/2 Trial Data on Investigational Drug Brigatinib Published in The Lancet Oncology
-
ARIAD Reports Third Quarter 2016 Financial Results
-
ARIAD to Present at the Jefferies 2016 London Healthcare Conference
-
ARIAD to Webcast Conference Call on Third Quarter 2016 Financial Results
-
ARIAD Pharma (ARIA) Announces U.S. FDA Acceptanct of Brigatinib NDA; Request for Priority Review Granted
-
ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Brigatinib
-
ARIAD Pharma (ARIA) Announces Publication of Brigatinib Preclinical Data in NSCLC
-
ARIAD Announces Publication of the Preclinical Profile of Brigatinib in the Journal Clinical Cancer Research
-
ARIAD Pharma (ARIA) volatility continues to move higher as shares trend lower
-
ARIAD Pharma (ARIA) Acknowledges Receipt of Congressional Letter; Issues Commentary
-
ARIAD Reaffirms Commitment to Discovering and Developing Treatments for Patients with Rare Cancers
-
ARIAD Pharma (ARIA) volatility increases after former presidential candidate Senator Bernie Sanders post to Twitter
-
ARIAD Pharma (ARIA) puts active after former presidential candidate Senator Bernie Sanders posted to Twitter
-
ARIAD Pharma (ARIA) Presents Updated Brigatinib Phase 1/2 Data in ALK+ NSCLC; 62% Achieved Objective Response
-
ARIAD Presents Updated Long-Term Follow-up Results from the Phase 1/2 Trial on Investigational Drug Brigatinib at 2016 ESMO Meeting
-
ARIAD Pharma (ARIA) Says Partner Otuska Pharma Received Approval in Japan for Iclusig
-
ARIAD Announces Regulatory Approval for Iclusig® (ponatinib) in Japan
-
Pre-Open Stock Movers 09/26: (ARRY) (CHMT) (GWPH) Higher; (PTIE) (DRRX) (SALE) Lower (more...)
-
ARIAD Pharma (ARIA) to Make Several Iclusig Presentation at John Goldman Conference
-
ARIAD Announces Ponatinib Data Presentations at European School of Haematology Annual John Goldman Conference on Chronic Myeloid Leukemia
-
ARIAD Pharma (ARIA) Announces Completion of Brigatinib NDA Rolling Submission to FDA
-
ARIAD Completes Rolling Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration
-
ARIAD to Present at the Morgan Stanley Global Healthcare Conference
-
ARIAD Reports Second Quarter and First Half 2016 Financial Results
-
ARIAD to Webcast Conference Call on Second Quarter 2016 Financial Results
-
ARIAD Announces Webcast of Its Annual Stockholders Meeting
-
ARIAD Pharma (ARIA) Announces Completion of Strategic Review; Details Growth Strategy, Reaffirms FY16 Outlook
-
ARIAD Completes Strategic Review and Announces Plans for Growth
-
ARIAD Pharma (ARIA) Inks Agreements for Iclusig Distribution in LatAm, Middle East/North Africa
-
ARIAD Announces Distribution Agreements for Iclusig® in Latin America and the Middle East/North Africa
-
ARIAD Pharma (ARIA) Submits Brigatinib NDA to FDA as ALK+ NSCLC Treatment
-
ARIAD Initiates Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration Ahead of Plan
-
ARIAD (ARIA) Announces Long-Term Data from Phase 2 Pace Clinical Trial
-
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
-
ARIAD to Host Analyst & Investor Day in New York City
-
ARIAD Pharma (ARIA) Announces Brigatinib Met Primary Endpoint in ALTA Trial
-
ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate and 12.9-Month Median Progression-Free Survival in ALTA Study
-
ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary AL
-
ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients
-
ARIAD Pharma (ARIA) Announces Completion of European Ops Sale to Incyte (INCY)
